Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Tubulis

Biotech & Life Sciences · Planegg, Germany · Founded 2019 Unicorn

Generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology

Valuation
$2.5–5B
Latest valuation · Apr/2026
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value
Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

30 investors on Tubulis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
BioMed Partners
HTGF
Seventure Partners
Bayern Kapital
Coparion
OCCIDENT
Series B+ 24 investors entered at this stage
LeXito
Deep Track Capital
ZweiKa Holding
Ludwig Maximilian University of Munich
EQT Ventures
Ascenta Capital
Wellington Management
Nextech
Venrock
Leibniz Association
Evotec
EQT Life Sciences
Frazier Life Sciences
Fund+
HSM Holding
South Lake Holding
Andera Partners
Leibniz Research Institute for Molecular Pharmacology
Falling Walls Foundation
Science Holding
FundPlus
Nextech Invest
Greendale Holding
EIT Health

Global footprint

Where Tubulis has talent and traffic

Workforce by country
🇩🇪 Germany · Planegg HQ
Book a demo for the full country breakdown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States57.6%
🇩🇪 Germany19.4%
🇧🇪 Belgium8.8%
🇮🇳 India5.9%
🇬🇧 United Kingdom5.3%
Top 5 markets shown

Market sentiment

What the market is saying about Tubulis

An AI-synthesized read of the highest-engagement posts about Tubulis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tubulis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles